Financial Data and Key Metrics Changes - Consolidated revenues for the third quarter reached $408 million, an 8% increase compared to the previous year [5][24] - Consolidated EBITDA totaled $38 million, maintaining healthy margins despite a shift in business mix [6][24] - The trailing twelve-month revenue to customer acquisition cost (CAC) ratio improved to 5.8x from 4.2x a year ago, indicating enhanced marketing efficiency [10][11] Business Line Data and Key Metrics Changes - Senior segment revenues totaled $169 million, with adjusted EBITDA of $46 million, resulting in a 27% EBITDA margin despite a 26% reduction in agent headcount [25][26] - Healthcare Services revenue grew 53% year-over-year to $190 million, with adjusted EBITDA of $6 million [29] - Life Insurance revenues increased by 13% to $46 million, with adjusted EBITDA more than doubling to $6 million, resulting in a 14% EBITDA margin [31] Market Data and Key Metrics Changes - The SelectRx business saw membership grow by 41% year-over-year, reaching 106,000 members [5][29] - The Medicare Advantage environment was characterized by a strong close rate despite a smaller agent force, with policies totaling 168,000, down less than 10% [12][26] Company Strategy and Development Direction - The company aims to enhance profitability in the Healthcare Services segment by refining membership parameters and focusing on efficiency [18][55] - Plans to increase agent hiring are underway to capitalize on market improvements, particularly in the Medicare Advantage space [42][43] - The opening of a new facility in Kansas is expected to drive long-term operational efficiency and margin expansion, although it may initially drag profitability [62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the final rate notice for Medicare Advantage, which is expected to improve carrier reimbursement rates and market conditions [60] - The company anticipates potential headwinds in the fourth quarter due to new beneficiary eligibility parameters and the ramp-up of the Kansas facility [32][62] - Overall, management remains confident in the business model's ability to generate operating leverage and shareholder value [66] Other Important Information - The company is facing a Department of Justice complaint related to the Medicare Advantage system but plans to mount a vigorous defense [21][22] - Significant progress has been made on the capital structure, including a $100 million securitization and a $350 million strategic investment [34][35] Q&A Session Summary Question: Can you walk through the separation of growth in Medicare Advantage and SelectRx? - Management noted that while there was a 26% reduction in agent count, the close rates were strong due to tenured agents, which helped drive efficiency and attach rates to SelectRx [37][39] Question: What are the plans for agent growth in the upcoming season? - Hiring is currently underway, with expectations to discuss more in the upcoming guidance [42][43] Question: Can you provide insights on the receivable securitization? - Management indicated that securitization is a potential path for capital structure optimization, with several options being explored [44][45] Question: How should investors think about MA LTV moving forward? - A decline in MA LTV is expected in the fourth quarter due to the shift in commission structure, with further details to be shared in the next earnings call [49][51] Question: What benefits are expected from the new Kansas facility? - The facility is anticipated to improve operating efficiency and customer experience, although there will be a short-term drag on profitability [61][62]

Financial Data and Key Metrics Changes - SelectQuote reported consolidated revenues of $408 million for Q3 2025, an 8% increase compared to the previous year [4][21] - Consolidated EBITDA for the quarter was $38 million, reflecting a margin of 9% despite a mix shift towards lower-margin Healthcare Services [5][21] - The trailing twelve-month revenue to customer acquisition cost (CAC) ratio improved to 5.8x from 4.2x a year ago, indicating enhanced marketing efficiency [9][10] Business Line Data and Key Metrics Changes - The Senior segment generated $169 million in revenue with an adjusted EBITDA of $46 million, achieving a margin of 27% despite a 26% reduction in agent headcount [22][24] - Healthcare Services revenue grew 53% year-over-year to $190 million, with adjusted EBITDA of $6 million [27] - Life Insurance revenues increased by 13% to $46 million, with adjusted EBITDA more than doubling to $6 million, resulting in a margin of 14% [29] Market Data and Key Metrics Changes - SelectQuote's SelectRx business saw membership grow to 106,000, a 41% increase year-over-year, contributing to significant revenue growth [4][27] - The company noted a favorable final rate notice for the 2026 plan year, which is expected to alleviate pressures in the Medicare Advantage market [7][58] Company Strategy and Development Direction - The company aims to enhance profitability in its Healthcare Services segment by refining membership parameters and focusing on efficiency [15][51] - SelectQuote plans to leverage its scale and improve margin consistency, even if it results in slower membership growth in the near term [16][51] - The company is committed to maintaining high integrity and compliance in the Medicare Advantage industry amid ongoing legal challenges [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the Medicare Advantage landscape, citing improved agent efficiency and customer attachment rates [36][38] - The company anticipates potential headwinds in Q4 due to new beneficiary eligibility parameters and the ramp-up of its Kansas distribution facility [30][62] - Management remains optimistic about the long-term growth prospects of the Healthcare Services segment, despite short-term profitability challenges [16][62] Other Important Information - SelectQuote has made significant progress on its capital structure, including a $100 million securitization and a $350 million strategic investment [31][32] - The company ended the quarter with an operating cash flow of $71 million and a cash balance of $86 million [32][33] Q&A Session Summary Question: Can you walk through the separation of growth in Medicare Advantage and SelectRx? - Management noted that while there was a decline in Medicare Advantage volume due to a smaller agent count, the efficiency of tenured agents helped drive strong performance in SelectRx [35][36] Question: What are the plans for agent growth in the upcoming season? - Management indicated that hiring is underway and they feel positive about the early stages of recruitment for the next season [40][42] Question: Can you discuss the impact of receivable securitization? - Management confirmed that they are exploring additional securitization options and have made progress on their capital structure [43][45] Question: How should investors think about MA LTV moving forward? - Management expects MA LTV to be down year-over-year in Q4 due to the shift in commission structure but will provide more details in the next earnings call [48] Question: What are the expected benefits from the new Kansas facility? - Management anticipates long-term benefits in operating efficiency and customer experience, although there will be a short-term drag on profitability [61][62]

Financial Performance - Revenue increased by 8% year-over-year, reaching $408.2 million in 3Q25 compared to $376.4 million in 3Q24[14] - Adjusted EBITDA decreased to $37.7 million in 3Q25 from $46.6 million in 3Q24[14] - The combined Senior and Healthcare Services Revenue-to-Customer Acquisition Cost (Rev-to-CAC) multiple was 5.8x[14] - The company anticipates full year 2025 revenue between $1500 billion and $1575 billion, representing a 16% year-over-year increase at the midpoint[38] - The company anticipates full year 2025 Adjusted EBITDA between $115 million and $140 million, representing a 9% year-over-year increase at the midpoint[38] - The company anticipates full year 2025 Net Income (Loss) between $(1) million and $28 million, representing a 140% year-over-year increase at the midpoint[38] Senior Segment - Approved Medicare Advantage (MA) policies exceeded forecasts, despite a 26% reduction in the number of agents, resulting in only a 10% decrease in MA policies[14] - Strong close rates contributed to robust performance and Adjusted EBITDA margins of 27% in 3Q25[14,17] - Total approved policies decreased from 202,000 in 3Q24 to 186,000 in 3Q25[30] - Medicare Advantage Lifetime Value (MA LTV) decreased from $995 in 3Q24 to $915 in 3Q25[30] Healthcare Services (SelectRx) - SelectRx membership grew by 41% year-over-year, reaching nearly 106,000 members in 3Q25[14,22] - SelectRx generated nearly $675 million in trailing 12-month revenue[22]

Exhibit 99.1 SelectQuote, Inc. Reports Third Quarter of Fiscal Year 2025 Results Third Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Fiscal Year 2025 Guidance Ranges: Third Quarter Fiscal Year 2025 – Segment Highlights Senior Healthcare Services Life OVERLAND PARK, Kan., May 12, 2025--(BUSINESS WIRE)--SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the third quarter of fiscal year 2025 of $408.2 million compared to consolidated revenue for the third quarter of fiscal year 2 ...

Core Viewpoint - SelectQuote's stock price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage sector [1][3]. Company Investigation - Hagens Berman is investigating SelectQuote for potential misconduct regarding its sales practices and disclosures, particularly in its Senior business that offers Medicare Advantage plans [2][4]. - The investigation is focused on whether SelectQuote's claims of providing unbiased advice and comparison shopping for Medicare plans were misleading [3][4]. Allegations Against SelectQuote - The DOJ's complaint alleges that from 2016 to at least 2021, SelectQuote and other brokers received substantial payments from insurers for enrollments into Medicare Advantage plans, which may have influenced their sales practices [7]. - It is claimed that SelectQuote directed beneficiaries to plans that provided the highest kickbacks, rather than those that were most suitable for the beneficiaries [7]. - The company allegedly incentivized employees to prioritize plans based on kickbacks and discriminated against Medicare Advantage beneficiaries with disabilities [7].

Core Viewpoint - The Schall Law Firm is investigating SelectQuote, Inc. for potential violations of securities laws related to misleading statements and undisclosed information [1][2]. Investigation Details - The investigation centers on claims that SelectQuote may have issued false or misleading statements and failed to disclose critical information to investors [2]. - A DOJ False Claims Act was filed against SelectQuote on May 1, 2025, alleging that from 2016 to at least 2021, insurers paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [2]. - Following the news of the investigation, SelectQuote's shares dropped by 16% on the same day [2].

Core Viewpoint - SelectQuote's share price dropped over 19% following a lawsuit filed by the U.S. Department of Justice, alleging violations of the False Claims Act related to its business practices in the Medicare Advantage market [1][3]. Group 1: Lawsuit and Allegations - The U.S. Department of Justice filed a lawsuit against SelectQuote and other insurance brokers, claiming they violated the False Claims Act [1]. - The investigation focuses on SelectQuote's disclosures regarding its sales practices, particularly in its Senior business offering Medicare Advantage plans [2]. - Allegations include that SelectQuote directed Medicare beneficiaries to plans that provided the highest kickbacks to brokers, rather than acting in the best interest of the beneficiaries [5]. Group 2: Financial Impact - Following the announcement of the lawsuit, SelectQuote's shares fell by over 19% on May 1, 2025 [1][3]. - The lawsuit raises concerns about the potential inflation of SelectQuote's financial results due to alleged steering practices [4]. Group 3: Whistleblower Information - Whistleblowers with non-public information regarding SelectQuote are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [4].

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE:SLQT). The investigation concerns whether SelectQuote and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that ...

NEW YORK, May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SelectQuote, Inc. ("SelectQuote" or the "Company") (NYSE: SLQT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether SelectQuote and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 1, 2025, the U ...

Core Points - Holzer & Holzer, LLC is investigating SelectQuote, Inc. for potential violations of federal securities laws related to a False Claims Act complaint filed by the Department of Justice [1] - The complaint alleges that SelectQuote received millions in kickbacks from Humana over six years, contingent upon specific Medicare Advantage enrollment targets and maintaining a dedicated sales force for Humana policies [1] - Following the announcement of the investigation, SelectQuote's stock price experienced a decline [1] Company Overview - SelectQuote, Inc. is publicly traded on the NYSE under the ticker SLQT [1] - The company has been implicated in a legal issue concerning its business practices and relationships with Humana [1] Legal Context - The Department of Justice's complaint highlights serious allegations of corporate misconduct involving kickbacks and improper business practices [1] - Holzer & Holzer, LLC is a law firm specializing in securities litigation, representing shareholders and investors in cases of corporate fraud [3]